Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Goodwin

Interventional Cardiology Naperville, IL Medical Doctor

NPI 1639125867 CMS profile 73447

10 Martin Ave Ste 200, Naperville, IL 60540

Open in the dashboard

General payments

$121,045

423 records reported · program years 2019–2025

Research payments

$12,028

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$161,303 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mark Goodwin of Naperville, IL is reported in the CMS Open Payments database as having received $121,045 across 423 general payments and $12,028 in research payments paid to them. Separately, studies naming them as principal investigator received $161,303 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,026 60
2024 General $13,587 80
2024 Research $459 3
2023 General $8,538 72
2023 Research $44 2
2022 General $2,103 38
2021 General $50,915 55
2020 General $2,950 30
2020 Research $9,375 6
2019 General $30,928 88
2019 Research $2,150 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Goodwin
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Mark Goodwin were reported at $12,026. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Mark Goodwin Interventional Cardiology median Middle half National median
2019 $30,928 $1,097 $329–$3,048 $163
2020 $2,950 $473 $161–$1,480 $114
2021 $50,915 $677 $233–$1,827 $132
2022 $2,103 $978 $333–$2,724 $149
2023 $8,538 $1,136 $382–$2,986 $160
2024 $13,587 $1,181 $395–$3,326 $164
2025 $12,026 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $62,704 110 payments
  2. Boston Scientific Corporation $19,235 55 payments
  3. Cordis US Corp. $15,886 17 payments
  4. Philips Electronics North America Corporation $8,940 12 payments
  5. Asahi Intecc USA, Inc. $3,080 42 payments
  6. Abbott Laboratories $2,147 33 payments
  7. Medtronic, Inc. $1,948 21 payments
  8. Siemens Medical Solutions USA, Inc. $1,291 7 payments
  9. Opsens Inc. $907 17 payments
  10. Shockwave Medical, Inc $629 4 payments
  11. Other $4,279 105 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $46,460 12 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,000 6 payments
  3. Travel and Lodging $20,125 37 payments
  4. Food and Beverage $20,096 351 payments
  5. Honoraria $10,750 4 payments
  6. Entertainment $612 12 payments
  7. Education $2 1 payment
Products named General payments · program years 2019–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $44,117 33 payments
  2. Edwards SAPIEN 3 Transcatheter Heart Valve $15,959 45 payments
  3. SELUTION SLR PTA $9,094 7 payments
  4. GENERAL VASCULAR ACCESS $9,093 5 payments
  5. (9547) IGT Systems Und $7,381 3 payments
  6. Cardio $6,238 4 payments
  7. WATCHMAN $3,500 1 payment
  8. STINGRAY $3,119 2 payments
  9. ASAHI PTCA Guide Wire $2,007 22 payments
  10. CorPath GRX $1,291 7 payments
  11. Other $16,410 275 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Philips Electronics North America Corporation $11,525 9 payments
  2. Abiomed $503 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

6,425

Median for Interventional Cardiology: 2,236

Drug cost

$649,823

Median for Interventional Cardiology: $380,412

Branded share of claims

23.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 174 $209,584
Xarelto Rivaroxaban Brand 153 $169,592
Entresto Sacubitril/Valsartan Brand 76 $77,091
Repatha Sureclick Evolocumab Brand 40 $46,823
Jardiance Empagliflozin Brand 24 $30,688
Brilinta Ticagrelor Brand 16 $13,504
Vascepa Icosapent Ethyl Brand 12 $12,830
Metoprolol Succinate Generic 729 $10,683
Clopidogrel Clopidogrel Bisulfate Brand 679 $7,606
Atorvastatin Calcium Generic 653 $7,053

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$343,584

Of which drugs: $3,411

Medicare patients

915

Average age 76

Services billed

4,281

407 women, 508 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 53%
Chronic kidney disease 37%
Diabetes 36%
Atrial fibrillation 35%
Heart failure 34%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, sulfur hexafluoride lipid microspheres, per ml Q9950 Office 39 200 $2,936

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $182
$182 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $54
$54 76 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $49
$49 24 —
ELIQUIS
  • PFIZER INC. $46
$46 174 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

437 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record